



### Ashley Allen Carr

**Associate**

ashley.carr@dlapiper.com

**Austin**

T: +1 512 457 7251

F: +1 512 721 2251

Ashley represents healthcare, life science, pharmaceutical, medical device, and technology companies in a variety of litigation matters, including complex commercial litigation and product liability cases. She also regularly counsels clients on a wide range of issues, including risk management and state and federal regulatory matters.

Ashley has significant experience in all phases of litigation, including strategic assessment and planning, investigations, fact and expert witness development, dispositive motion practice, discovery, and trials in both state and federal courts. Ashley has taken and defended numerous expert and fact witness depositions in a wide range of commercial litigation cases and has argued motions in both state and federal courts. She also has briefed cases in numerous federal and state appellate courts and has argued before Texas's Third Court of Appeals.

Beyond the healthcare space, Ashley's practice spans several areas, including general business litigation, securities litigation, insurance, and arbitration matters. She has a successful track record representing clients in the financial services, technology, energy, real estate and insurance industries.

Ashley serves on the Board of the Travis County Women Lawyers' Association and is a co-founder of The Greenfield Project, a non-profit organization that conducts legal and regulatory analyses to develop and promote policy initiatives that support sustainable, humane agricultural practices. Ashley also maintains an active pro bono practice. She has served as pro bono counsel for the Animal Legal Defense Fund and for several individual clients in family law, criminal, and immigration matters. Ashley is a recipient of the Judge Thomas Gibbs Gee award for outstanding pro bono service.

- Litigation, Arbitration and Investigations
- Product Liability, Mass Torts and Product Stewardship

- Life Sciences
- Healthcare
- Technology

## Admissions

- Texas

## Prior Experience

Prior to joining DLA Piper, Ashley practiced litigation in the Austin office of an international law firm.

## Education

- J.D., Harvard Law School 2012
- B.A., Rice University 2008  
*magna cum laude*  
Phi Beta Kappa

## Courts

- United States Court of Appeals for the Fifth Circuit
- United States District Court for the Eastern District of Texas
- United States District Court for the Northern District of Texas
- United States District Court for the Western District of Texas

## Memberships

- Member, DLA Piper Associate Advisory Council

## INSIGHTS

---

### Publications

#### PREP Act immunity: federal courts weigh in

4 September 2020

The decisions suggest PREP Act immunity may apply broadly to manufacturers but may be more limited for hospitals, nursing homes, healthcare providers and others.

---

#### HHS clarifies PREP Act immunity for COVID-19-related activities

28 April 2020

These immunity provisions may provide significant protection to manufacturers, distributors, and others engaged in COVID-19-related efforts.

---

#### Importing critical healthcare supplies during the COVID-19 pandemic: Recent US developments

31 March 2020

Practical guidance is critical to help importers of medical products efficiently navigate legal and regulatory hurdles so that admissible products with the potential to safeguard patients' health and well-being may be granted entry into US markets as expeditiously as possible.

---

#### Potential paths forward amidst the challenges to COVID-19 therapeutic and vaccine development; collaboration and communication among clinical trial stakeholders takes on heightened importance (United States)

20 March 2020

In a March 19, 2020, briefing and press release, the US Food and Drug Administration outlined ways that existing regulatory options may make it possible to expedite access to therapeutics and vaccines with the potential to treat or prevent coronavirus disease 2019 (COVID-19).

---

**COVID-19: As diagnostic companies and laboratories ask “how can I help?” FDA responds with unprecedented regulatory flexibility, seeking to achieve more rapid testing capacity in the US**

18 March 2020

Options expand for life science, healthcare and other stakeholders.

---

Co-author, "Pandemic Creates Extra Cyber Risk For Health Care Providers," *Law360*, April 30, 2020

## [Events](#)

## [Previous](#)

### **Building a vaccination plan: Key considerations for businesses**

18 February 2021 | 9:00 - 10:00 PT

Webinar

---